Patents by Inventor William R. Fair
William R. Fair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100310452Abstract: This invention provides an isolated nucleic acid molecule encoding an alternatively spliced human prostate-specific membrane antigen. This invention provides an isolated nucleic acid comprising a promoter sequence normally associated with the transcription of a gene encoding a human prostate-specific membrane antigen. This invention provides an isolated polypeptide having the biological activity of an alternatively spliced prostate-specific membrane antigen. This invention provides a method of detecting a nucleic acid encoding an alternatively spliced human prostate-specific membrane antigen and a method of detecting a prostate tumor cell in a subject. Lastly, this invention provides a pharmaceutical composition comprising a compound in a therapeutically effective amount and a pharmaceutically acceptable carrier and a method of making prostate cells susceptible to a cytotoxic chemotherapeutic agent.Type: ApplicationFiled: October 24, 2001Publication date: December 9, 2010Inventors: Ron S. Israeli, Warren D.W. Heston, William R. Fair, Ouathek Ouerfelli, John Pinto
-
Publication number: 20100303715Abstract: This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM?) antigen. This invention provides an isolated nucleic acid molecule encoding a prostate-specific membrane antigen promoter. This invention provides a method of detecting hematogenous micrometastic tumor cells of a subject, and determining prostate cancer progression in a subject.Type: ApplicationFiled: September 11, 2009Publication date: December 2, 2010Inventors: Ron S. Israeli, Warren D.W. Heston, William R. Fair, Maryann Fair
-
Patent number: 7105159Abstract: This invention provides purified antibodies to the outer membrane domain of prostate-specific membrane (PSM) antigen, compositions of matter comprising PSM antigen antibodies conjugated to a radioisotope or a toxin, and a method of imaging prostate cancer by using PSM antigen antibodies.Type: GrantFiled: June 6, 1995Date of Patent: September 12, 2006Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
-
Patent number: 7070782Abstract: The invention provides a purified prostate-specific membrane antigen.Type: GrantFiled: June 7, 1995Date of Patent: July 4, 2006Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
-
Patent number: 7037647Abstract: This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM?) antigen. This invention provides an isolated nucleic acid molecule encoding a prostate-specific membrane antigen promoter. This invention provides a method of detecting hematogenous micrometastic tumor cells of a subject, and determining prostate cancer progression in a subject.Type: GrantFiled: February 23, 1996Date of Patent: May 2, 2006Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
-
Patent number: 6953668Abstract: This invention provides for an isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This invention provides for nucleic acid probes which specifically hybridize with the nucleic acid molecule encoding said antigen. This invention provides for a method of detecting hematogenous micrometastic tumor cells of a subject performing the polymerase chain reaction (PCR) on samples of the subject using primers of said antigen. This invention provides for methods to identify ligands which bind to said antigen. This invention provides for the prevention and/or treatment of prostate tumor growth.Type: GrantFiled: June 6, 1995Date of Patent: October 11, 2005Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
-
Publication number: 20040253246Abstract: This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM′) antigen.Type: ApplicationFiled: January 2, 2004Publication date: December 16, 2004Inventors: Ron S. Israeli, Warren D.W. Heston, William R. Fair
-
Publication number: 20040001846Abstract: This invention provides an isolated nucleic acid molecule encoding an alternatively spliced human prostate-specific membrane antigen. This invention provides an isolated nucleic acid comprising a promoter sequence normally associated with the transcription of a gene encoding a human prostate-specific membrane antigen. This invention provides an isolated polypeptide having the biological activity of an alternatively spliced prostate-specific membrane antigen.Type: ApplicationFiled: May 21, 2003Publication date: January 1, 2004Applicant: Sloan-Kettering Institute For Cancer ResearchInventors: Ron S. Israeli, Warren D.W. Heston, William R. Fair, Ouathek Ouerfelli, John Pinto
-
Patent number: 6569432Abstract: This invention provides an isolated nucleic acid molecule encoding an alternatively spliced human prostate-specific membrane antigen. This invention provides an isolated nucleic acid comprising a promoter sequence normally associated with the transcription of a gene encoding a human prostate-specific membrane antigen. This invention provides an isolated polypeptide having the biological activity of an alternatively spliced prostate-specific membrane antigen. This invention provides a method of detecting a nucleic acid encoding an alternatively spliced human prostate-specific membrane antigen and a method of detecting a prostate tumor cell in a subject. Lastly, this invention provides a pharmaceutical composition comprising a compound in a therapeutically effective amount and a pharmaceutically acceptable carrier and a method of making prostate cells susceptible to a cytotoxic chemotherapeutic agent.Type: GrantFiled: August 29, 1996Date of Patent: May 27, 2003Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair, Ouathek Ouerfelli, John Pinto
-
Patent number: 5935818Abstract: This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM') antigen. This invention provides an isolated nucleic acid molecule encoding a prostate-specific membrane antigen promoter. This invention provides a method of detecting hematogenous micrometastic tumor cells of a subject, and determining prostate cancer progression in a subject.Type: GrantFiled: February 24, 1995Date of Patent: August 10, 1999Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
-
Patent number: 5538866Abstract: This invention provides an isolated mammalian nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This invention also provides prostate-specific membrane nucleic acid of at least 15 nucleotides capable of specifically hybridizing with a sequence of a nucleic acid molecule encoding a mammalian prostate-specific membrane antigen. This invention further provides vector and vector host expression system for the prostate-specific membrane antigen. This invention also provides methods to identify ligands which bind to the prostate-specific membrane antigen, to generate antibody against a complete prostate-specific membrane antigen or a portion of the antigen. This invention further provides purified prostate-specific membrane antigen. This invention provides a therapeutic agent comprising an antibody directed against to prostate-specific membrane antigen and a cytotoxic agent conjugated thereto.Type: GrantFiled: October 18, 1994Date of Patent: July 23, 1996Assignee: Sloan-Kettering Institute For Cancer ResearchInventors: Ron S Israeli, Warren D. W. Heston, William R. Fair
-
Patent number: 4671254Abstract: This invention relates to a method for the non-surgical treatment of tumors. The method of this invention involves the use of shock waves to effect subcellular destruction of tumor cells, to alter their tumorigenic potential, and to suppress tumor growth.Type: GrantFiled: March 1, 1985Date of Patent: June 9, 1987Assignee: Memorial Hospital for Cancer and Allied DiseasesInventor: William R. Fair
-
Patent number: RE43586Abstract: This invention provides purified antibodies to the outer membrane domain of prostate-specific membrane (PSM) antigen, compositions of matter comprising PSM antigen antibodies conjugated to a radioisotope or a toxin, and a method of imaging prostate cancer by using PSM antigen antibodies.Type: GrantFiled: September 12, 2008Date of Patent: August 14, 2012Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair, Maryann Fair, legal representative